- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05286372
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
An Intermediate Size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Expanded Access Type
- Intermediate-size Population
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936
- Hispanic Alliance for Research & Translational Research
-
-
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Oakland, California, United States, 94612
- The Kaiser Permanente Medical Group
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Holy Cross Health
-
Fort Lauderdale, Florida, United States, 32608
- Nova Southeastern University
-
Gainesville, Florida, United States, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- The Sean M. Healey & AMG Center for ALS Massachusetts General Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Neurology Associates, P.C. / Somnos Clinical Research
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Weinberg ALS Center
-
-
Texas
-
El Paso, Texas, United States, 79995
- Texas Tech University Health Sciences Center El Paso
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington School of Medicine
-
Seattle, Washington, United States, 98122
- Swedish Neuroscience Institute
-
Spokane, Washington, United States, 99202
- Providence St. Luke's Rehabilitation Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, at least 18 years of age (inclusive);
- Diagnosis of ALS made by a physician experienced with the management of ALS;
- >36 months from symptom onset defined as first weakness
- Capable of providing informed consent;
- Capable of and willing to follow program procedures.
- Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program.
Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the program and 3 months after last dose of AMX0035;
- Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug
Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug;
- Men must not plan to father a child or provide sperm
Exclusion Criteria
- Currently enrolled in a therapeutic study involving the use of an investigational therapy;
Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening;
- No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks
- In the judgment of the Investigator, the participant's expected survival is less than 6 months
- History of known allergy to the following: PB, bile salts, excipient/constituents of the formulation;
- Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the normal (obtained within 12 weeks from first dose);
- Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks from first dose);
- Pregnant women or women currently breastfeeding;
- Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder;
- History of Class III/IV heart failure (per New York Heart Association - NYHA);
- Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment;
- Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment;
- Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment;
- Treatment, current or within 90 days from screening with any cell therapies or gene therapies;
- Implantation of Diaphragm Pacing System (DPS);
- Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program;
- Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A35-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on AMX0035
-
Amylyx Pharmaceuticals Inc.Massachusetts General Hospital Neurology Clinical Research InstituteCompletedAmyotrophic Lateral Sclerosis | ALSUnited States
-
Amylyx Pharmaceuticals Inc.Active, not recruiting
-
Amylyx Pharmaceuticals Inc.RecruitingNeurodegenerative Diseases | Progressive Supranuclear Palsy | Atypical Parkinsonism | PSPUnited States
-
Amylyx Pharmaceuticals Inc.CompletedAmyotrophic Lateral SclerosisUnited States
-
Amylyx Pharmaceuticals Inc.Enrolling by invitationAmyotrophic Lateral SclerosisBelgium, Spain, Netherlands, United Kingdom, Sweden, France, Germany, Ireland, Italy, Poland, Portugal
-
Amylyx Pharmaceuticals Inc.Active, not recruitingAmyotrophic Lateral SclerosisUnited States, Belgium, Spain, Netherlands, United Kingdom, Germany, Sweden, France, Ireland, Italy, Poland, Portugal
-
Amylyx Pharmaceuticals Inc.Active, not recruiting
-
Amylyx Pharmaceuticals Inc.ALS Association; ALS Finding a Cure; Northeast ALS Consortium; Neurological Clinical... and other collaboratorsCompletedCentral Nervous System Diseases | Nervous System Diseases | Neuromuscular Diseases | Neurodegenerative Diseases | Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Spinal Cord Diseases | TDP-43 ProteinopathiesUnited States
-
Amylyx Pharmaceuticals Inc.Alzheimer's Association; Alzheimer's Drug Discovery FoundationCompletedAlzheimer DiseaseUnited States